Janux Therapeutics (JANX) Preferred Stock Liabilities (2020 - 2021)
Janux Therapeutics' (JANX) quarterly Preferred Stock Liabilities came in at $77.3 million in Q1 2021, up 257.69% on a QoQ basis from $21.6 million in Q4 2020.
Janux Therapeutics (JANX) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Janux Therapeutics (JANX) has 2 years of Preferred Stock Liabilities data on file, last reported at $77.3 million in Q1 2021.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $77.3 million in Q1 2021; TTM through Mar 2021 was $77.3 million, a N/A change from a year earlier, with the FY2020 full-year figure at $21.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q1 2021 stood at $77.3 million, up from $21.6 million in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for JANX reached as high as $77.3 million in Q1 2021 and fell as low as $17.1 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Janux Therapeutics | 985.11 Mn | 985.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 77.35 Mn |
| Dec 31, 2020 | 21.62 Mn |
| Sep 30, 2020 | 17.13 Mn |
| Jun 30, 2020 | 17.13 Mn |